by Carol Westbrook
The Golden Age of cancer research is here. The Human Genome program provided rapid sequencing tools and large databases to be mined, computers are larger and faster than ever, advances in equipment and robotics make high-throughput experiments possible, the info web permits quick literature searches…. and so on. Cancer patients are out there, digitally connected and eager to participate in clinical trials. An increasing amount of private and public monies are going into the research effort. We are poised to make great discoveries at a rapid pace, and bring them rapidly to the clinics.
So then, why are these anticipated advances in cancer treatment so slow in coming? What is wrong with cancer research today? Well, pretty much everything.
Cancer research has two sides to it: the basic science laboratory at the university, where ideas are generated and potential new treatments are designed, and the clinical research program, where these new drugs are tested on patients and developed into bona fide treatments which are then brought to the FDA and eventually the marketplace and clinic. There are inefficiencies and major barriers to productivity in both the basic and clinical arenas.
Laboratory research is terribly expensive, and relies primarily on government funding, though an increasing amount comes from private donations and foundations. Yet only a fraction of these research dollars are truly used for researc, as the university is permitted to keep a large share as “overhead” for its own use. Admittedly, these dollars support the teaching mission of the university and contribute to our country's education, but that's fewer dollars spent on cancer research.
There is intense competition for these research dollars, and the competition itself is costly, requiring large infrastructures merely to submit and review grants. One's success in academics relies on getting the most grant money, rather than on the productivity that results from the grant.


